Skip to search formSkip to main contentSkip to account menu

18F-FPPRGD2

Known as: 18F-FP-PEG3-RGD2, [18F] FPPRGD2, 18F-FP-PRGD2 
A radiopharmaceutical agent comprised of a pegylated dimeric arginine-glycine-aspartic acid (RGD)-based peptide labeled with 2-fluoropropionyl, with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PurposeThe usefulness of positron emission tomography/computed tomography (PET/CT) using (18F)-2-fluoropropionyl-labeled… 
2015
2015
PurposeWe report the effect of antiangiogenic therapy on the biodistribution of 18F-FPPRGD2 (a surrogate biomarker of integrin αv… 
2015
2015
PurposeThe aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine… 
Review
2014
Review
2014
PURPOSE To present data from the first prospective pilot phase trial of breast cancer participants imaged with fluorine 18 ((18)F… 
2014
2014
Glutamic acid is a commonly used linker to form dimeric peptides with enhanced binding affinity than their corresponding… 
2012
2012
PurposeNon-invasive PET imaging with radiolabeled RGD peptides for αvβ3 integrin targeting has become an important tool for tumor… 
Highly Cited
2011
Highly Cited
2011
Abraxane (nanoparticle albumin-bound paclitaxel) is an anticancer drug approved by the Food and Drug Administration. However, the… 
2011
2011
RGD peptides, radiolabeled with 18F, have been used in the clinic for PET imaging of tumor angiogenesis in cancer patients. RGD… 
2011
2011
PurposeWe evaluated noninvasive positron emission tomography (PET) imaging for monitoring tumor response to the VEGFR-2 tyrosine… 
Highly Cited
2009
Highly Cited
2009
PurposeIn vivo imaging of αvβ3 has important diagnostic and therapeutic applications. 18F-Galacto-arginine–glycine–aspartic acid…